dence that prostaglandins play an important role in the pathogenesis of premature labor [14] . Prostaglandins synthetase inhibitors are known relaxants of the gravid uterus. The nonsteroid antiinflammatory agents such as aspirin, indomethacin, salicylic acid, naproxen, meclofenamic acid are potent inhibitors of prostaglandin biosynthesis in the body. The purpose of this study was to test the efficacy and safety of indomethacin in suppressing the premature labor and expands a previously reported study [30] . In the first part of the study prospective uncontrolled large group of patients treated with indomethacin for premature labor were evaluated for efficacy and safety and in second part (see the following article) a double blind study was conducted.
Materials and methods
A trial of indomethacin was conducted in 297 women in premature labor. The patients were aged between 16 and 44 years. There were 120 primiparas and 177 multiparas. The gestational age at admission varied between 24 and 34 completed weeks of pregnancy. There were 45 patients with premature rupture of membranes. Patients were admitted to the trial if regular, painful contractions were occurring at frequency of two or more in 10 minutes. In all patients uterine activity was recorded with external cardiotocography during a control period of at least 30 minutes to obtain a baseline of activity before indomethacin was administered. Patients with suspected intra-uterine growth retardation, toxemia, uterine malformations, fever, vaginal bleeding, oligohydramnios and polyhydramnios were excluded. Every patient received 100mg of indomethacin (rectally) in suppository form followed by 25 mg (orally) every 6 hours until the contractions had been inhibited for 24 hours. If uterine contractions continued after the initial rectal dose of indomethacin the patient received an additional 100 mg suppository after 1 hour and then the treatment was continued orally. The total daily dose needed for successful treatment was between 200 and 300 mg of indomethacin and the patient was under hospital observation during 1 to 2 days. No other drugs were used and all patients gave informed consent to the study. Treatment was considered to have been successful when the premature contractions were arrested completely for more than 1 week. Where uterine activity ceased for between 48 hours and 7 days, treatment was considered to be of moderate value. The treatment was considered ineffective if contractions could not be stopped or if they commenced again and delivery took place within 48 hours of the start of therapy. Maternal pulse and blood pressure, uterine contractions and fetal heart rate were monitored during treatment. The criterion for prematurity was a birth age of less than 37 weeks gestation confirmed at delivery by the criteria described by DUBOWITZ et al. [6] .
Results
The effect of indomethacin treatment on premature labor was evaluated by cessation of uterine contractions and the period of prolongation of gestation. Thirty minutes after indomethacin administration uterine contractions decreased in frequency and intensity and complete uterine relaxation was noted within 2-13 hours. Tab. I shows the results of indomethacin treatment. After indomethacin treatment premature labor stopped completely for 1 to 12 weeks in 83% of patients. In 10% the treatment was of moderate value, i.e. the uterine contractions were stopped for 2 to 7 days. The 7 % of the patients in which the treatment was ineffective were delivered in 48 hours. Indomethacin was less effective in cases in which the cervix was dilated more than 4 cm whereas uterine contractions were arrested completely in 90% of the cases where the cervical dilatation was 3 cm or less. When the dilation was more than 3 cm the contractions were stopped in only 58% of the cases. Premature labor also more readily suppressed in women with intact membranes (88 %) compared with those with ruptured membranes (53%). In most cases the delay in delivery ranged from 5-9 weeks although in 49 patients delivery was delayed as much as 11-12 weeks (Tab. II). In 48 patients it was necessary to repeat the treatment as contractions reappeared after 2 week interval. Fifty-one premature babies were born in spite of therapy and 15 of these (5 % of the all group) died from respiratory distress syndrome (weights of 700-1500 g). The remaining 36 premature infants and the 246 mature infants were in good condition at birth and were all examined by a pediatrician. Meconium was noted in the amniotic fluid in 18 cases (6%) and no ill effects relating to the treatment were observed. The development of these children who were seen at follow-up examination during a period of up to 5 years of age, was satisfactory. Where labor was not supressed the course of labor and delivery was completely normal with no increased need for obstetrical interference. Indomethacin therapy did not alter maternal blood pressure or pulse rate or fetal heart rate. Minor side effects were seen however including nausea, vomiting and dyspepsia (8 patients), maculopapular eruption (2 patients) and epistaxis (1 patient). All symptoms disappeared within a few hours of discontinuing therapy. Our study of 297 women shows that indomethacin completely inhibited premature labor in 83 % of the patients. A moderate effect was achieved in 10% of patients and this delay of premature labor for 2 to 7 days allowed the administration of betamethasone in an attempt to improve fetal lung maturity. The inhibitory effect of indomethacin on uterine contractions and the subsequent delay of delivery, decreased with the progress of cervical dilatation and with the presence of ruptured membranes. These results compare favorably with other reported series using oral indomethacin alone [4, 29] or oral therapy following unsuccessful administration of beta-sympathomimetic agents [8] . The total dose administered was usually higher and the duration of administration was usually longer in these series however.
The main theoretical problem associated with the administration of indomethacin is the possibility of this agent causing premature closure of the ductus arteriosus. Case reports claiming to demonstrate a correlation between the ingestion of prostaglandin antagonists and congenital ductus closure [2] , and primary neonatal pulmonary hypertension [17] are not well substantiated and do not take into account the thousands of women suffering from rheumatoid arthritis who are exposed to large doses of these drugs during pregnancy without any apparent deleterious effect on the fetal circulation. SHAPIRO et al. [22] reported that among 40,000 pregnant women (25,000 were treated with aspirin and 15,000 were a control group) no change in perinatal mortality was seen. A variation in the sensitivity of the ductus arteriosus to indomethacin at different gestations in the rat has been clearly demonstrated by SHARPE et al. [23, 24] . Maximal sensitivity to this drug was found only when it was adminstered 12-18 hours prior to delivery at term, whereas administration at 18 days of age (premature) had no effect at all. The lack of deleterious effect on the cardiovascular system in our group of infants may have been due to the fact the indomethacin was not given when the gestation exceeded 35 weeks, and similar reasons could explain the lack of complications reported by other workers using indomethacin to inhibit premature labor [4, 8, 18, 25, 29] . It is of interest, however, that even when indomethacin was administered within 24 hours of delivery at term [20] no fetal cardiovascular complications occurred. Because of the virtual complete absence of maternal side effects, patient acceptance of the therapy is much higher than when treatment with beta-adrenergic drugs has been proposed.
Summary
Prematurity still remains one of the unsolved problems in obstetrics and is responsible for a majority of cases of perinatal morbidity and mortality. The use of indomethacin to stop uterine contractions and prevent premature delivery is based on the observation that indomethacin inhibits the release of prostaglandin which is assumed to play a role in the induction and continuation of labor. The effect of indomethacin as an antagonist to prostaglandin was evaluated in a series of 297 women in premature labor. The gestational age at admission varied between 24 and 34 weeks of pregnancy (120 primiparas and 177 multiparas). In 83 % of cases there was complete cessation of labor for a period of 1 to 12 weeks, in 10 % of cases from 2 to 7 days and in 7 % there was no effect. The delay of premature labor for 2 to 7 days allowed the administration of betamethasone in an attempt to improve fetal lung maturity. The total daily dose needed for successful treatment was between 200-300 mg indomethacin. Dilation of cervix beyond 4 cm was associated with successful treatment in 58% compared to 90% if cervix was dilated 3 cm or less. In comparing women with intact membranes to women with ruptured, the success rate in suppressing premature labor was significant; 88% versus 53%. In 49 patients delivery was delayed 11-12 weeks. Fifty-one babies were born in spite of therapy, and of these 15 with birth weights of 700-1500 g suffered from respiratory distress syndrome and died. All the rest (36 premature and 246 mature infants) showed no ill effects related to the treatment. During a 5 years followup period of these children, normal development was seen in all cases. No intoward effects were observed on maternal or fetal wellbeing during and after treatment. Minor side effects such as nausea, vomiting and dyspepsia occured in 8 patients, a maculopapular eruption occured in 2 patients and epistaxis in 1 patient. These side effects disappeared a few hours after stopping the medication. The results suggest that indomethacin is an effective and well tolerated inhibitor of premature labor.
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